Atossa Therapeutics, Inc. (ATOS)
Largest Insider Buys in Sector
ATOS Stock Price History Chart
ATOS Stock Performance
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with …
Insider Activity of Atossa Therapeutics, Inc.
Over the last 12 months, insiders at Atossa Therapeutics, Inc. have bought $44,250 and sold $0 worth of Atossa Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Atossa Therapeutics, Inc. have bought $46,375 and sold $316,167 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Finn Jonathan (director) — $44,250.
The last purchase of 25,000 shares for transaction amount of $44,250 was made by Finn Jonathan (director) on 2024‑04‑10.
List of Insider Buy and Sell Transactions, Atossa Therapeutics, Inc.
| 2024-04-10 | director | 25,000 0.0202% | $1.77 | $44,250 | -20.00% | |||
| 2023-11-15 | Sale | Former EVP, CFO, & Director | 50,000 0.0395% | $0.65 | $32,500 | +100.30% | ||
| 2023-06-20 | EVP & CFO | 50,000 0.0401% | $0.97 | $48,500 | -1.04% | |||
| 2021-07-02 | Sale | director | 107,497 0.0883% | $5.58 | $599,833 | -69.09% | ||
| 2017-11-15 | CFO, Gen Counsel and Secretary | 10,000 0.0857% | $0.34 | $3,369 | -23.53% | |||
| 2017-04-17 | director | 2,500 0.0345% | $0.63 | $1,580 | -24.59% | |||
| 2016-04-01 | director | 1,500 0.0044% | $0.33 | $495 | -57.08% | |||
| 2016-03-09 | President & CEO | 15,000 0.0476% | $0.37 | $5,550 | -59.37% | |||
| 2016-03-09 | 15,000 0.0476% | $0.37 | $5,550 | -59.37% | ||||
| 2016-02-16 | President & CEO | 15,000 0.0459% | $0.53 | $7,950 | -54.55% | |||
| 2016-02-16 | 15,000 0.0459% | $0.53 | $7,950 | -54.55% | ||||
| 2016-01-19 | President & CEO | 50,000 0.1586% | $0.20 | $10,000 | +30.00% | |||
| 2016-01-19 | 50,000 0.1586% | $0.20 | $10,000 | +30.00% | ||||
| 2015-06-12 | director | 5,400 0.02% | $1.30 | $7,020 | -62.99% | |||
| 2013-11-21 | director | 20,000 0.1359% | $2.58 | $51,570 | -30.41% | |||
| 2013-10-01 | Sale | CEO | 14,530 0.0922% | $5.66 | $82,211 | -67.88% | ||
| 2013-10-01 | Sale | Chief Scientific Officer | 14,530 0.0922% | $5.66 | $82,211 | -67.88% | ||
| 2013-05-15 | director | 1,000 0.0068% | $5.49 | $5,490 | -55.87% | |||
| 2013-01-08 | director | 6,000 0.0447% | $4.14 | $24,820 | +17.39% |
Insider Historical Profitability
| Finn Jonathan | director | 25000 0.0199% | $1.03 | 1 | 0 | |
| QUAY STEVEN C | President & CEO | 4826858 3.8369% | $1.03 | 3 | 1 | <0.0001% |
| Chen Shu-Chih | 4348315 3.4565% | $1.03 | 3 | 1 | <0.0001% | |
| CROSS ALEXANDER D | director | 88866 0.0706% | $1.03 | 1 | 0 | |
| Guse Kyle | CFO, Gen Counsel and Secretary | 10000 0.0079% | $1.03 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $10.36M | 4.58 | 5.75M | +1.38% | +$140,884.20 | <0.0001 | |
| BlackRock | $4.95M | 2.19 | 2.75M | -1.61% | -$81,313.19 | <0.0001 | |
| Laurion Capital Management LP | $4.01M | 1.77 | 2.23M | 0% | +$0 | 0.03 | |
| Renaissance Technologies | $2.5M | 1.1 | 1.39M | +7.95% | +$183,745.68 | <0.01 | |
| Geode Capital Management | $2.18M | 0.96 | 1.21M | +8.74% | +$175,362.52 | <0.0001 |